SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 22, 2014--
Exelixis, Inc. (Nasdaq: EXEL) today announced that it plans to offer,
subject to market and other conditions, 10,000,000 shares of its common
stock in an overnight underwritten public offering. The company expects
to grant the underwriter a 30-day option to purchase up to an additional
1,500,000 shares of common stock in connection with the offering. All of
the shares of common stock in the offering will be sold by Exelixis.
Subject to market and other conditions, the offering is expected to
price before 9:30 a.m., EST, on January 23, 2014.
Cowen and Company is acting as underwriter for the offering. The
offering is being conducted by means of a prospectus supplement filed as
part of a shelf registration statement previously filed with the
Securities and Exchange Commission (SEC) on Form S-3.
This announcement does not constitute an offer to sell or a solicitation
of an offer to buy nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. This press release is
being issued pursuant to and in accordance with Rule 134 under the
Securities Act of 1933, as amended. Any offer, if at all, will be made
only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. Copies of the
preliminary prospectus supplement and base prospectus relating to the
offering may be obtained, when available, from Cowen and Company, LLC
(c/o Broadridge Financial Services., 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax:
631-254-7140). Exelixis intends to file a preliminary prospectus
supplement relating to the offering with the SEC, which will be
available along with the prospectus filed with the SEC in connection
with the shelf registration statement, on the SEC’s website at http://www.sec.gov.
About Exelixis
Exelixis is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements relating to Exelixis’ expectations regarding the completion,
timing and size of the proposed public offering. These statements are
subject to significant risks and uncertainties and actual results could
differ materially from those projected. Exelixis cautions investors not
to place undue reliance on the forward-looking statements contained in
this release. These risks and uncertainties include, without limitation,
risks and uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering. There can
be no assurance that Exelixis will be able to complete the public
offering on the anticipated terms, or at all. Risks and uncertainties
relating to Exelixis and its business can be found in the “Risk Factors”
section of Exelixis’ Form 10-Q, filed with the SEC on October 30, 2013,
and in the preliminary prospectus supplement related to the proposed
offering to be filed with the SEC. Exelixis undertakes no duty or
obligation to update any forward-looking statements contained in this
release as a result of new information, future events or changes in
Exelixis’ expectations.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Corporate
Communications & Investor Relations
cbutler@exelixis.com